Cara, Vifor Pharma score speedy FDA nod on itching drug for CKD — shares surge
The FDA has approved Cara Therapeutics and Vifor Pharma’s Korsuva (difelikefalin), a novel kappa opioid receptor agonist injection to treat severe-to-moderate pruritis, or itching, in patients with chronic kidney disease undergoing dialysis, the companies said Monday.
The partners expect to launch in Q1, they said in a statement, and are currently assembling a reimbursement package with the Centers for Medicare and Medicaid Services for submission.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.